You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

DEXTROAMPHETAMINE SULFATE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Dextroamphetamine Sulfate patents expire, and what generic alternatives are available?

Dextroamphetamine Sulfate is a drug marketed by Able, Actavis Elizabeth, Dr Reddys Labs Sa, Nesher Pharms, Norvium Bioscience, Specgx Llc, Strides Pharma, Prasco, Tris Pharma Inc, Ani Pharms, Aurolife Pharma Llc, Avanthi Inc, Azurity, Barr, Epic Pharma Llc, Halsey, Lannett, Mast Mm, Novel Labs Inc, Nuvo Pharm, Purepac Pharm, Sandoz, Vitarine, and Winder Labs Llc. and is included in thirty-three NDAs.

The generic ingredient in DEXTROAMPHETAMINE SULFATE is dextroamphetamine sulfate. There are eighteen drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the dextroamphetamine sulfate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Dextroamphetamine Sulfate

A generic version of DEXTROAMPHETAMINE SULFATE was approved as dextroamphetamine sulfate by BARR on January 31st, 2001.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for DEXTROAMPHETAMINE SULFATE?
  • What are the global sales for DEXTROAMPHETAMINE SULFATE?
  • What is Average Wholesale Price for DEXTROAMPHETAMINE SULFATE?
Summary for DEXTROAMPHETAMINE SULFATE
Drug patent expirations by year for DEXTROAMPHETAMINE SULFATE
Drug Prices for DEXTROAMPHETAMINE SULFATE

See drug prices for DEXTROAMPHETAMINE SULFATE

Recent Clinical Trials for DEXTROAMPHETAMINE SULFATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Vallon Pharmaceuticals, Inc.Phase 1
Medical University of ViennaN/A
Centre hospitalier de l'Université de Montréal (CHUM)Phase 2

See all DEXTROAMPHETAMINE SULFATE clinical trials

Pharmacology for DEXTROAMPHETAMINE SULFATE
Medical Subject Heading (MeSH) Categories for DEXTROAMPHETAMINE SULFATE

US Patents and Regulatory Information for DEXTROAMPHETAMINE SULFATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Epic Pharma Llc DEXTROAMPHETAMINE SULFATE dextroamphetamine sulfate TABLET;ORAL 090652-001 Mar 7, 2014 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Azurity DEXTROAMPHETAMINE SULFATE dextroamphetamine sulfate TABLET;ORAL 090533-001 Oct 25, 2011 AA RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Nesher Pharms DEXTROAMPHETAMINE SULFATE dextroamphetamine sulfate TABLET;ORAL 206588-001 Mar 28, 2016 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.